Furukawa, Natsuki http://orcid.org/0000-0001-5771-917X
Yang, Wendy
Chao, Alex R.
Patil, Akash http://orcid.org/0000-0002-4175-9107
Mirando, Adam C. http://orcid.org/0000-0003-0602-3011
Pandey, Niranjan B.
Popel, Aleksander S.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA138264, P30 CA006973, R01CA138264)
U.S. Department of Health & Human Services | National Institutes of Health (S10OD016374)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Takenaka Scholarship Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 19 September 2023
Revised: 21 March 2024
Accepted: 25 March 2024
First Online: 2 April 2024
Competing interests
: NBP is the VP of R&D and ACM is a Senior Scientist at AsclepiX Therapeutics, Inc., ASP is a consultant to AsclepiX. Their work with AsclepiX focuses on unrelated peptides with no overlap with the current project. ASP is also a consultant to J&J/Janssen and Incyte. Other authors declare no competing interests. The terms of these arrangements are being managed by Johns Hopkins University in accordance with its conflict-of-interest policies.